Early virologic responses and hematologic safety of direct-acting antiviral therapies in veterans with chronic hepatitis C

Clinical Gastroenterology and Hepatology

Volumn 11, Issue 8, 2013, Pages 1021-1027

  Belperio, Pamela S ^a   Hwang, Elizabeth W ^a,b   Thomas, I Chun ^a   Mole, Larry A ^a   Cheung, Ramsey C ^a,b   Backus, Lisa I ^a  

^a VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cirrhosis; Protease inhibitor; SVR; Therapy

Indexed keywords

BOCEPREVIR; HEMOGLOBIN; PEGINTERFERON; RIBAVIRIN; TELAPREVIR;

ADULT; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; FEMALE; GENOTYPE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; NEUTROPHIL COUNT; RELAPSE; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; VETERAN;

APRI; ASPARTATE AMINOTRANSFERASE/PLATELET RATIO INDEX; BOC; BOCEPREVIR; CIRRHOSIS; DAA; DIRECT-ACTING ANTIVIRAL; HCV; HEPATITIS C VIRUS; ICD-9; INTERNATIONAL CLASSIFICATION OF DISEASES, 9TH REVISION; ODDS RATIO; OR; PEG; PEGYLATED INTERFERON; PROTEASE INHIBITOR; RBV; RIBAVIRIN; SUSTAINED VIROLOGIC RESPONSE; SVR; TELAPREVIR; THERAPY; TVR; VA; VETERANS AFFAIRS;

AGED; ANEMIA; ANTIVIRAL AGENTS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; MALE; MIDDLE AGED; OLIGOPEPTIDES; PROLINE; PROSPECTIVE STUDIES; RIBAVIRIN; TREATMENT OUTCOME; VETERANS; VIRAL LOAD;

EID: 84880628355     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2013.03.006     Document Type: Article

References (26)

1. George S.L., Bacon B.R., Brunt E.M., et al. Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients. Hepatology 2009, 49:729-738.
2. Pearlman B.L., Traub N. Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more. Clin Infect Dis 2011, 52:889-900.
3. D'Ambrosio R., Aghemo A., Rumi M.G., et al. A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis. Hepatology 2012, 56:532-543.
4. Backus L.I., Boothroyd D.B., Phillips B.R., et al. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol 2011, 9:509-516.
5. McHutchison J.G., Lawitz E.J., Shiffman M.L., et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009, 361:580-593.
6. Fried M.W., Shiffman M.L., Reddy K.R., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347:975-982.
7. State of Care for Veterans with Chronic Hepatitis C Accessed: August 29, 2012. http://www.hepatitis.va.gov/provider/policy/HCV-state-of-care-2010.asp.
8. Kramer J.R., Kanwal F., Richardson P., et al. Gaps in the achievement of effectiveness of HCV treatment in national VA practice. J Hepatol 2012, 56:320-325.
9. Backus L.I., Boothroyd D.B., Phillips B.R., et al. Predictors of response of US veterans to treatment for the hepatitis C virus. Hepatology 2007, 46:37-47.
10. Poordad F., McCone J., Bacon B.R., et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011, 364:1195-1206.
11. Jacobson I.M., McHutchison J.G., Dusheiko G., et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011, 364:2405-2416.
12. Bacon B.R., Gordon S.C., Lawitz E., et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011, 364:1207-1217.
13. Zeuzem S., Andreone P., Pol S., et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011, 364:2417-2428.
14. Ghany M.G., Nelson D.R., Strader D.B., et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011, 54:1433-1444.
15. Pearlman B.L. Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care. Lancet Infect Dis 2012, 12:717-728.
16. Pawlotsky J.M. The results of phase III clinical trials with telaprevir and Boceprevir. Presented at the Liver Meeting 2010: A New Standard of Care for Hepatitis C Virus genotype 1 Infection, but With Issues Still Pending. Gastroenterology 2011, 140:746-760.
17. Butt A.A., Khan U.A., McGinnis K.A., et al. Co-morbid medical and psychiatric illness and substance abuse in HCV-infected and uninfected veterans. J Viral Hepat 2007, 14:890-896.
18. Louie K.S., St Laurent S., Forssen U.M., et al. The high comorbidity burden of the hepatitis C virus infected population in the United States. BMC Infect Dis 2012, 12:86.
19. Vallet-Pichard A., Mallet V., Nalpas B., et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest. Hepatology 2007, 46:32-36.
20. Wai C.T., Greenson J.K., Fontana R.J., et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003, 38:518-526.
21. Victrelis. (Boceprevir) capsules for oral use 2011, Merck Sharp & Dohme, Corp, Whitehouse Station, NJ, Accessed: July 12, 2012. http://www.merck.com/product/usa/pi_circulars/v/victrelis/victrelis_pi.pdf.
22. Incivek. (Telaprevir) film coated tablets product information 2011, Vertex Pharmaceuticals, Inc, Cambridge, MA, Accessed: July 12, 2012. http://pi.vrtx.com/files/uspi_telaprevir.pdf.
23. McHutchison J.G., Manns M.P., Muir A.J., et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010, 362:1292-1303.
24. Bronowicki J.P., Davis M., Flamm S., et al. Sustained virologic response (SVR) in prior peginterferon/ribavirin (PR) treatment failures after retreatment with Boceprevir (BOC) +. PR: PROVIDE Study Interim Results. J Hepatology 2012, 56(S2):S6.
25. Adda N., Bartels D.J., Gritz L., et al. Futility rules for telaprevir combination treatment for patients with hepatitis C virus infection. Clin Gastroenterol Hepatol 2013, 11:193-195.
26. Holmes J.A., Desmond P.V., Thompson A.J. Does IL28B genotyping still have a role in the era of direct-acting antiviral therapy for chronic hepatitis C infection?. J Viral Hepat 2012, 19:677-684.